Concure Oncology Raises Additional $2M in Funding

cancer

Concure Oncology, a Mercer Island, Wash.-based provider of a radiation treatment option for women to face early-stage breast cancer, secured another $2m in funding.

The company intends to use the funds to further grow its organization and train new clinicians across the country to bring this treatment option to even more women.

Led by Scott Armstrong, CEO, Concure Oncology provides Breast Microseed Treatment®, which delivers radiation therapy to patients with early-stage breast cancer. This technique, also known as low-dose-rate brachytherapy, is based on a similar method that has already been proven to successfully treat prostate cancer. It allows post-lumpectomy patients the chance to have a one-time, one-hour procedure, as opposed to the more burdensome conventional radiation that may last from three to six weeks and require daily visits to a radiation facility. 

The procedure involves the placement of tiny, low dose-rate brachytherapy sources – or Microseeds – into the breast tissue, which release a safe but effective dose of radiation for 2-3 months to the immediate area surrounding the lumpectomy site. Once fully released, the seeds become inert, with no radioactivity remaining.

The Seattle area company is working with medical centers across the U.S. to bring Breast Microseed Treatment® to patients everywhere.

FinSMEs

03/11/2020

Join the discussion